These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 22149274)

  • 1. Epitope characterization of sero-specific monoclonal antibody to Clostridium botulinum neurotoxin type A.
    Corbett CR; Ballegeer E; Weedmark KA; Elias MD; Al-Saleem FH; Ancharski DM; Simpson LL; Berry JD
    Hybridoma (Larchmt); 2011 Dec; 30(6):503-10. PubMed ID: 22149274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fine and domain-level epitope mapping of botulinum neurotoxin type A neutralizing antibodies by yeast surface display.
    Levy R; Forsyth CM; LaPorte SL; Geren IN; Smith LA; Marks JD
    J Mol Biol; 2007 Jan; 365(1):196-210. PubMed ID: 17059824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of the monoclonal antibody response to botulinum neurotoxin type A in the complexed and uncomplexed forms.
    Zhao H; Nakamura K; Kohda T; Mukamoto M; Kozaki S
    Jpn J Infect Dis; 2012; 65(2):138-45. PubMed ID: 22446121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular characterization of murine humoral immune response to botulinum neurotoxin type A binding domain as assessed by using phage antibody libraries.
    Amersdorfer P; Wong C; Chen S; Smith T; Deshpande S; Sheridan R; Finnern R; Marks JD
    Infect Immun; 1997 Sep; 65(9):3743-52. PubMed ID: 9284147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epitope characterization and variable region sequence of f1-40, a high-affinity monoclonal antibody to botulinum neurotoxin type a (Hall strain).
    Scotcher MC; McGarvey JA; Johnson EA; Stanker LH
    PLoS One; 2009; 4(3):e4924. PubMed ID: 19290051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutralizing human monoclonal antibodies binding multiple serotypes of botulinum neurotoxin.
    Garcia-Rodriguez C; Geren IN; Lou J; Conrad F; Forsyth C; Wen W; Chakraborti S; Zao H; Manzanarez G; Smith TJ; Brown J; Tepp WH; Liu N; Wijesuriya S; Tomic MT; Johnson EA; Smith LA; Marks JD
    Protein Eng Des Sel; 2011 Mar; 24(3):321-31. PubMed ID: 21149386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent neutralization of botulinum neurotoxin/B by synergistic action of antibodies recognizing protein and ganglioside receptor binding domain.
    Chen C; Wang S; Wang H; Mao X; Zhang T; Ji G; Shi X; Xia T; Lu W; Zhang D; Dai J; Guo Y
    PLoS One; 2012; 7(8):e43845. PubMed ID: 22952786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of the antibody response to the receptor binding domain of botulinum neurotoxin serotypes A and E.
    Baldwin MR; Tepp WH; Pier CL; Bradshaw M; Ho M; Wilson BA; Fritz RB; Johnson EA; Barbieri JT
    Infect Immun; 2005 Oct; 73(10):6998-7005. PubMed ID: 16177380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mapping of the antibody-binding regions on the HN-domain (residues 449-859) of botulinum neurotoxin A with antitoxin antibodies from four host species. Full profile of the continuous antigenic regions of the H-chain of botulinum neurotoxin A.
    Atassi MZ; Dolimbek BZ
    Protein J; 2004 Jan; 23(1):39-52. PubMed ID: 15115181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization.
    Smith TJ; Lou J; Geren IN; Forsyth CM; Tsai R; Laporte SL; Tepp WH; Bradshaw M; Johnson EA; Smith LA; Marks JD
    Infect Immun; 2005 Sep; 73(9):5450-7. PubMed ID: 16113261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of neutralizing scFv-Fc against botulinum neurotoxin A light chain from a macaque immune library.
    Miethe S; Rasetti-Escargueil C; Liu Y; Chahboun S; Pelat T; Avril A; Frenzel A; Schirrmann T; Thullier P; Sesardic D; Hust M
    MAbs; 2014; 6(2):446-59. PubMed ID: 24492304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of a highly neutralizing single monoclonal antibody to botulinum neurotoxin type A.
    Brier S; Rasetti-Escargueil C; Wijkhuisen A; Simon S; Marechal M; Lemichez E; Popoff MR
    FASEB J; 2021 May; 35(5):e21540. PubMed ID: 33817838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Engineered domain-based assays to identify individual antibodies in oligoclonal combinations targeting the same protein.
    Meng Q; Garcia-Rodriguez C; Manzanarez G; Silberg MA; Conrad F; Bettencourt J; Pan X; Breece T; To R; Li M; Lee D; Thorner L; Tomic MT; Marks JD
    Anal Biochem; 2012 Nov; 430(2):141-50. PubMed ID: 22922799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Production and characterization of a neutralizing antibody against botulinum neurotoxin A.
    Xiong X; Lv S; Fu C; Li L; Sun Z; Han X; Zhang W
    J Immunol Methods; 2020 Dec; 487():112871. PubMed ID: 33007319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralizing antibodies of botulinum neurotoxin serotype A screened from a fully synthetic human antibody phage display library.
    Yu R; Wang S; Yu YZ; Du WS; Yang F; Yu WY; Sun ZW
    J Biomol Screen; 2009 Sep; 14(8):991-8. PubMed ID: 19726786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isolation of nanomolar scFvs of non-human primate origin, cross-neutralizing botulinum neurotoxins A1 and A2 by targeting their heavy chain.
    Avril A; Miethe S; Popoff MR; Mazuet C; Chahboun S; Rasetti-Escargueil C; Sesardic D; Thullier P; Hust M; Pelat T
    BMC Biotechnol; 2015 Sep; 15():86. PubMed ID: 26382731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extraction and inhibition of enzymatic activity of botulinum neurotoxins/A1, /A2, and /A3 by a panel of monoclonal anti-BoNT/A antibodies.
    Kalb SR; Lou J; Garcia-Rodriguez C; Geren IN; Smith TJ; Moura H; Marks JD; Smith LA; Pirkle JL; Barr JR
    PLoS One; 2009; 4(4):e5355. PubMed ID: 19399171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of highly sensitive chemiluminescence enzyme immunoassay based on the anti-recombinant H(C) subunit of botulinum neurotoxin type A monoclonal antibodies.
    Liu Z; Song C; Li Y; Liu F; Zhang K; Sun Y; Li H; Wei Y; Xu Z; Zhang C; Yang A; Xu Z; Yang K; Jin B
    Anal Chim Acta; 2012 Jul; 735():23-30. PubMed ID: 22713913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hybridoma populations enriched for affinity-matured human IgGs yield high-affinity antibodies specific for botulinum neurotoxins.
    Adekar SP; Jones RM; Elias MD; Al-Saleem FH; Root MJ; Simpson LL; Dessain SK
    J Immunol Methods; 2008 Apr; 333(1-2):156-66. PubMed ID: 18313069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-level expression of the Hcc domain of Clostridium botulinum neurotoxin serotype A in Escherichia coli and its immunogenicity as an antigen.
    Yu YZ; Sun ZW; Wang S; Yu WY
    Sheng Wu Gong Cheng Xue Bao; 2007 Sep; 23(5):812-7. PubMed ID: 18051857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.